Disposition of 145795 shares by Frisbee Allison of Kronos BioInc at 1.08 subject to Rule 16b-3

KRON Stock  USD 0.96  0.02  2.04%   
About 58% of Kronos Bio's investor base is looking to short. The analysis of the overall investor sentiment regarding Kronos Bio suggests that many traders are alarmed. Kronos Bio's investing sentiment overview a quick insight into current market opportunities from investing in Kronos Bio. Many technical investors use Kronos Bio stock news signals to limit their universe of possible portfolio assets and to time the market correctly.
  
Filed transaction by Kronos BioInc Officer: Sr Vp, Corp Operations & Legal. Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

Read at macroaxis.com
Disposition of 145795 stock option (right to buy) at 1.08 of Kronos BioInc by Frisbee Allison on 16th of February 2024. This event was filed by Kronos BioInc with SEC on 2024-02-16. Initial filing of beneficial ownership - SEC Form 3

Cash Flow Correlation

Kronos Bio's cash-flow correlation analysis can be used to evaluate the unsystematic risk during the given period. It also helps investors identify the Kronos Bio's relationships between the major components of the statement of changes in financial position and other commonly used cash-related accounts. When such correlations are discovered, they may help managers and analysts to enhance performance or determine appealing investment opportunities.
Click cells to compare fundamentals

Kronos Bio Investor Sentiment by Other News Outlets

Investor sentiment, mood or attitude towards Kronos Bio can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.

Kronos Bio Fundamental Analysis

We analyze Kronos Bio's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Kronos Bio using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Kronos Bio based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Revenue

Revenue Comparative Analysis

Kronos Bio is currently under evaluation in revenue category among its peers. Revenue is income that a firm generates from business activities such us rendering services or selling goods to customers. It is a crucial part of a business and an essential item when evaluating a company's financial statements. Revenues from a firm's primary business operations can be reported on the income statement as sales revenue, net sales, or simply sales, depending on the industry in which a given company operates.

Kronos Bio Potential Pair-trading

One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Kronos Bio stock to make a market-neutral strategy. Peer analysis of Kronos Bio could also be used in its relative valuation, which is a method of valuing Kronos Bio by comparing valuation metrics with similar companies.

Peers

Kronos Bio Related Equities

EWTXEdgewise Therapeutics   18.36   
0%
67.0%
LYRALyra Therapeutics   5.56   
0%
20.0%
CYCNCyclerion Therapeutics   4.08   
0%
14.0%
NVCTNuvectis Pharma   3.62   
0%
13.0%
CTMXCytomX Therapeutics   3.60   
0%
13.0%
ERASErasca   2.34   
0%
8.0%
CRNXCrinetics Pharmaceuticals   1.81   
0%
6.0%
ASMBAssembly Biosciences   1.04   
0%
3.0%
ADXNAddex Therapeutics   0.63   
0%
2.0%
MRUSMerus BV   0.28   
0%
1.0%
INBXInhibrx   0.00   
0%
0%
REPLReplimune   0.56   
2.0%
0%
GBIOGeneration Bio   0.86   
3.0%
0%
CCCCC4 Therapeutics   1.83   
6.0%
0%
SPROSpero Therapeutics   2.73   
10.0%
0%
ACHLAchilles Therapeutics   2.94   
10.0%
0%
NXTCNextCure   6.48   
23.0%
0%
GOSSGossamer Bio   7.53   
27.0%
0%
LYELLyell Immunopharma   11.84   
43.0%
0%
LRMRLarimar Therapeutics   27.23   
100.0%
0%
When determining whether Kronos Bio offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Kronos Bio's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Kronos Bio Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Kronos Bio Stock:
Check out Kronos Bio Hype Analysis, Kronos Bio Correlation and Kronos Bio Performance.
To learn how to invest in Kronos Stock, please use our How to Invest in Kronos Bio guide.
You can also try the FinTech Suite module to use AI to screen and filter profitable investment opportunities.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Kronos Bio. If investors know Kronos will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Kronos Bio listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(1.43)
Revenue Per Share
0.143
Quarterly Revenue Growth
0.442
Return On Assets
(0.28)
Return On Equity
(0.63)
The market value of Kronos Bio is measured differently than its book value, which is the value of Kronos that is recorded on the company's balance sheet. Investors also form their own opinion of Kronos Bio's value that differs from its market value or its book value, called intrinsic value, which is Kronos Bio's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Kronos Bio's market value can be influenced by many factors that don't directly affect Kronos Bio's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Kronos Bio's value and its price as these two are different measures arrived at by different means. Investors typically determine if Kronos Bio is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Kronos Bio's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.